{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:28:09Z","timestamp":1777559289904,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["JAIN21A1"],"award-info":[{"award-number":["JAIN21A1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["JAIN20Y7"],"award-info":[{"award-number":["JAIN20Y7"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.chest.2024.05.019","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:20:26Z","timestamp":1718072426000},"page":"951-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis"],"prefix":"10.1016","volume":"166","author":[{"given":"Melanie","family":"Holtrop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3861-5866","authenticated-orcid":false,"given":"Sophia","family":"Cosmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-506X","authenticated-orcid":false,"given":"MinJae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.chest.2024.05.019_bib1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oxfordjournals.aje.a009172","article-title":"Gender gap in cystic fibrosis mortality","volume":"145","author":"Rosenfeld","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.chest.2024.05.019_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0895-4356(94)00230-N","article-title":"Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection","volume":"48","author":"Demko","year":"1995","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.chest.2024.05.019_bib3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic fibrosis","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.chest.2024.05.019_bib4","first-page":"1","article-title":"Summary health statistics for the U.S. population: National Health Interview Survey, 2001","volume":"217","author":"Barnes","year":"2003","journal-title":"Vital Health Stat"},{"issue":"3 pt 2","key":"10.1016\/j.chest.2024.05.019_bib5","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1164\/ajrccm\/151.3_Pt_2.S47","article-title":"The cystic fibrosis transmembrane conductance regulator gene","volume":"151","author":"Tsui","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.chest.2024.05.019_bib6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A\u00a0CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.chest.2024.05.019_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10212","key":"10.1016\/j.chest.2024.05.019_bib8","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.chest.2024.05.019_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11882-015-0528-y","article-title":"Asthma is different in women","volume":"15","author":"Zein","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/j.chest.2024.05.019_bib10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"The ENFUMOSA Cross-sectional European Multicentre Study of the Clinical Phenotype of Chronic Severe Asthma","volume":"22","year":"2003","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.05.019_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1164\/rccm.201004-0665OC","article-title":"Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience","volume":"183","author":"Celli","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2024.05.019_bib12","first-page":"1145","article-title":"Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes","volume":"9","author":"Aryal","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccm.2004.01.011","article-title":"Bronchiectasis: sex and gender considerations","volume":"25","author":"Morrissey","year":"2004","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijmyco.2015.05.002","article-title":"Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis","volume":"4","author":"Mirsaeidi","year":"2015","journal-title":"Int J Mycobacteriol"},{"issue":"7","key":"10.1016\/j.chest.2024.05.019_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.chest.2024.05.019_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/17476348.2022.2090928","article-title":"Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies","volume":"16","author":"Oates","year":"2022","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17476348.2017.1280399","article-title":"Adherence to therapies in cystic fibrosis: a targeted literature review","volume":"11","author":"Narayanan","year":"2017","journal-title":"Expert Rev Respir Med"},{"issue":"suppl 3","key":"10.1016\/j.chest.2024.05.019_bib18","first-page":"S74","article-title":"The demographics of adverse outcomes in cystic fibrosis","volume":"54","author":"McGarry","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"12 pt 1","key":"10.1016\/j.chest.2024.05.019_bib19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1164\/rccm.200202-087OC","article-title":"Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality","volume":"166","author":"Mayer-Hamblett","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.chest.2024.05.019_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A\u00a0comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.chest.2024.05.019_bib23","series-title":"Second paperback ed","article-title":"Analysis of Longitudinal Data","author":"Diggle","year":"2013"},{"issue":"8","key":"10.1016\/j.chest.2024.05.019_bib24","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1164\/rccm.201909-1845LE","article-title":"Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males","volume":"201","author":"Secunda","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib25","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2020.05.004","article-title":"Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor\/ivacaftor compared to males","volume":"20","author":"Aalbers","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","article-title":"Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Wang","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2024.05.019_bib28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.chest.2024.05.019_bib29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2024.05.019_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ppul.22767","article-title":"Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men","volume":"49","author":"Sutton","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1164\/rccm.201001-0053OC","article-title":"17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor","volume":"182","author":"Chotirmall","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2024.05.019_bib34","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1513\/AnnalsATS.202008-1064OC","article-title":"A\u00a0prospective study of the effects of sex hormones on lung function and inflammation in women with cystic fibrosis","volume":"18","author":"Holtrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"10.1016\/j.chest.2024.05.019_bib35","doi-asserted-by":"crossref","first-page":"e00422","DOI":"10.1128\/IAI.00422-17","article-title":"17beta-Estradiol dysregulates innate immune responses to pseudomonas aeruginosa respiratory infection and is modulated by estrogen receptor antagonism","volume":"85","author":"Abid","year":"2017","journal-title":"Infect Immun"},{"issue":"159","key":"10.1016\/j.chest.2024.05.019_bib36","doi-asserted-by":"crossref","first-page":"200293","DOI":"10.1183\/16000617.0293-2020","article-title":"Cystic fibrosis-related diabetes and lung disease: an update","volume":"30","author":"Prentice","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.chest.2024.05.019_bib38","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcf.2022.03.012","article-title":"Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D","volume":"21","author":"Hoppe","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"17","key":"10.1016\/j.chest.2024.05.019_bib39","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.3390\/ijms21176379","article-title":"Airway inflammation and host responses in the era of CFTR modulators","volume":"21","author":"Keown","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.chest.2024.05.019_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.chest.2024.05.019_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ppul.25179","article-title":"Cystic fibrosis with non-G551D gating mutations in Italy: epidemiology and clinical characteristics","volume":"56","author":"Salvatore","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.chest.2024.05.019_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal trends in real-world outcomes after initiation of ivacaftor. A cohort study from the Cystic Fibrosis Registry of Ireland","volume":"16","author":"Kirwan","year":"2019","journal-title":"Ann Am Thorac Soc"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224006986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224006986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:25:23Z","timestamp":1777400723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224006986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0012369224006986"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.05.019","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex Differences After Treatment With Ivacaftor in People With Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}